On Instagram, Dr Olivier Marpeau aka @mon.gyneco, in collaboration with the Institut Curie, Stéphanie Descroix, present tumors on a chip. This technology does not yet choose routine treatments, but it opens up a concrete avenue: testing, in the laboratory, the sensitivity of mini-tumor models to certain drugs.
A mini-tumor in the laboratory, not a computer chip
Stéphanie Descroix, CNRS research director at the Institut Curie, works on tumor-on-chip models. On Instagram, she shows a very small device containing tanks and chambers where cells can be placed. The principle is based on microfluidics: circulating or organizing very small volumes of liquids in miniaturized structures.
The point is not to copy the entire tumor of a patient, which would be impossible, but to reconstruct certain key elements of its microenvironment. Because a tumor is not just a cluster of cancer cells: it interacts with neighboring cells, immune cells, fibroblasts, a matrix which gives it an architecture and mechanical signals.
In the video, Stéphanie Descroix explains that researchers can start from a tumor, dissociate it, recover different cell types, then replace them in a collagen matrix. She uses a very telling image: the collagen fibers look like spaghetti, in the middle of which the cells are positioned in 3D, like elements dispersed in a structure.
In other words, the tumor on a chip makes it possible to manufacture small controlled versions of a tumor environment. It is precisely this control that interests research teams: it makes it possible to vary certain parameters and observe what changes.
Why this technology is of interest to personalized medicine
These models are not only used to “see” a tumor. They can also help to understand how it works. Stéphanie Descroix compares this approach to a cooking recipe: to understand the role of an ingredient, you can add it, remove it, then observe the effect of this modification.
Applied to breast cancer, this reasoning can help researchers analyze how tumor cells communicate with their environment, how they evolve, or even why some seem more sensitive than others to a treatment. This is a complementary logic to the personalization of cancer treatments, already largely driven by the analysis of the biological and molecular characteristics of tumors.
In current treatment, certain therapeutic decisions are already based on validated biomarkers, in particular to guide targeted therapies against breast cancer. Tumors on a chip involve another approach, called functional: instead of only characterizing the tumor, we observe how a model derived from this tumor reacts under experimental conditions.
This is what fuels the hope of more personalized medicine: from a biopsy, making several chips and evaluating the response to
certain treatments for which the patient is eligible. But this hope must be expressed with caution: it is not a universal test nor a guarantee of response in the sick person.
A promising avenue, still being validated
The important point is here: tumors on a chip are not today a standard of care for all patients with breast cancer. The available work shows potential, but clinical utility must still be confirmed before broad integration into medical decisions.
A recent study carried out by teams at the Institut Curie, for example, evaluated a tumor-on-a-chip platform to rapidly test drugs in breast cancer. The results suggest that a sensitivity profile can be obtained within a few days in a research setting, with good agreement with some experimental models. However, the authors speak of a potential for clinical transfer, not of a tool already routinely validated.
We must also avoid an idea that is too simple: no, these chips do not allow us to “test everything” in all conditions. The protocols evaluate precise drug panelschosen according to the context, and certain treatments – particularly those which strongly depend on complex immune interactions – cannot always be modeled in the same way.
For patients, the practical message is therefore measured: this technology opens an interesting way to better understand breast cancers and, perhaps tomorrow, refine certain therapeutic choices. But treatment decisions remain the responsibility of the oncology teambased on validated data available for each situation.